<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095337</url>
  </required_header>
  <id_info>
    <org_study_id>SHR1459-I-108</org_study_id>
    <nct_id>NCT05095337</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of [14C]SHR1459 in Chinese Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Mass Babance and Biotransformation of [14C]SHR1459 in Healthy Adult Male&#xD;
      Volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity ratio for blood/plasma</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative recovery of total radioactive substances in urine and/or feces;</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of metabolites in urine and feces in dose administration (% of dose administration) or percentage of circulating metabolites in plasma in total exposure AUC (%AUC);</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Evevts(AEs) and Serious Adverse Events.</measure>
    <time_frame>up to Day 21 (approx) from the start of administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Adult Male Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]SHR1459</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]SHR1459</intervention_name>
    <description>Patients will receive single dose of orally [14C]SHR1459 on Day 1.</description>
    <arm_group_label>[14C]SHR1459</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing the informed consent forms;&#xD;
&#xD;
          2. Healthy adult males;&#xD;
&#xD;
          3. Age: 18 Years to 45 Years(Including the boundary value);&#xD;
&#xD;
          4. Weight: Body mass index(BMI) between 19 and 26 kg/m2(Including the boundary value);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidates who meet any of the following conditions will not be selected:&#xD;
&#xD;
        Laboratory examination:&#xD;
&#xD;
          1. Complete physical examination, laboratory examination (blood routine, blood&#xD;
             biochemistry, urine routine, coagulation function, fecal occulted blood, thyroid&#xD;
             function (FT3, FT4, TSH), 12-lead electrocardiogram, Xchest X-ray (orthostatic&#xD;
             position), abdominal B-ultrasound (liver, bile, pancreas, spleen, kidney) and other&#xD;
             abnormal and clinically significant examinations;&#xD;
&#xD;
          2. Ophthalmologic examination (slit lamp, intraocular pressure and fundus photography)&#xD;
             with abnormal clinical significance;&#xD;
&#xD;
          3. Hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and&#xD;
             syphilis antibody, any of which are positive.&#xD;
&#xD;
             Medical history:&#xD;
&#xD;
          4. Screening for use of any clinical trial drug within the first 3 months or withdrawal&#xD;
             time shorter than the 6 half-life period of the trial drug at enrollment, whichever is&#xD;
             the longest of the two;&#xD;
&#xD;
          5. CYP3A4 and CYP2C9 inducers or inhibitors were taken within 28 days before screening,&#xD;
             as shown in Appendix 1.&#xD;
&#xD;
          6. Use of any prescription or over-the-counter drug, any vitamin product, health care&#xD;
             drug or Chinese herbal medicine within 14 days prior to screening;&#xD;
&#xD;
             Medical history and treatment history:&#xD;
&#xD;
          7. clinical symptoms or diseases of the heart that cannot be well controlled, such as&#xD;
             :(1) heart failure of NYHA2 or above; (2) unstable angina pectoris; (3) myocardial&#xD;
             infarction within 1 year; (4) supraventral or ventricular arrhythmia with clinical&#xD;
             significance that requires treatment or intervention; (5) QTcF&gt;450ms(male) at&#xD;
             screening stage; (5) QTcF&gt;450ms.&#xD;
&#xD;
          8. Patients who had undergone major surgery or whose surgical incision was not completely&#xD;
             healed within 6 months before the screening period;Major surgery includes, but is not&#xD;
             limited to, any surgery with a significant risk of bleeding, prolonged general&#xD;
             anesthesia, or an open biopsy or significant traumatic injury;&#xD;
&#xD;
          9. Screening for abdominal fistula, gastrointestinal perforation or abdominal abscess in&#xD;
             the first 6 months;&#xD;
&#xD;
         10. Screening for clinically significant bleeding symptoms or definite bleeding tendency,&#xD;
             such as gastrointestinal bleeding and bleeding ulcer, in the first 3 months;&#xD;
&#xD;
         11. Hemorrhoids or perianal diseases with regular/bleeding in the stool;Patients with&#xD;
             gastrointestinal dysfunction, such as irritable bowel syndrome and inflammatory bowel&#xD;
             disease, may be affected by drug absorption as determined by researchers;&#xD;
&#xD;
         12. Allergic persons, including those with a history of severe drug allergy or drug&#xD;
             allergy, and those with known allergy to SHR6390 or similar drugs and&#xD;
             excipients;Allergic to any food ingredients or has special requirements on diet,&#xD;
             cannot follow the unified diet;&#xD;
&#xD;
         13. A history of any clinically serious illness or condition, including but not limited to&#xD;
             circulatory, endocrine, nervous, digestive, urinary, or blood, immune, mental, and&#xD;
             metabolic diseases, that the investigator considers to be likely to affect the results&#xD;
             of the study;&#xD;
&#xD;
             Living Habits:&#xD;
&#xD;
         14. Habitual constipation or diarrhea;&#xD;
&#xD;
         15. Heavy drinking or regular drinking in the six months preceding the screening period,&#xD;
             i.e. drinking more than 14 units of alcohol per week (1 unit =285 mL beer or 25 mL&#xD;
             spirits of 40% alcohol or 100 mL wine);Or alcohol breath test results at screening&#xD;
             period ≥20 mg/ dL;&#xD;
&#xD;
         16. Those who had smoked more than 5 cigarettes per day on average in the 3 months before&#xD;
             the screening period or habitually used nicotinecontaining products and were unable to&#xD;
             quit during the test period;&#xD;
&#xD;
         17. Substance abuse or use of soft drugs (e.g., marijuana) in the 3 months prior to the&#xD;
             screening period or use of hard drugs (e.g., cocaine, amphetamines,&#xD;
             phenylcyclohexidine, etc.) in the 1 year prior to the screening period;Or screening&#xD;
             for positive urine drug abuse (drug) tests;&#xD;
&#xD;
         18. habitual consumption of grapefruit juice or excessive consumption of tea, coffee&#xD;
             and/or caffeinated beverages and failure to abstain during the study period;&#xD;
&#xD;
             Other:&#xD;
&#xD;
         19. Those with a history of fainting needle or blood, have difficulty in blood collection&#xD;
             or cannot tolerate vein puncture for blood collection;&#xD;
&#xD;
         20. Workers engaged in conditions requiring long-term exposure to radioactivity;Or have&#xD;
             significant radiation exposure (≥2 chest/abdomen CT, or ≥3 other types of X-ray&#xD;
             examinations) within 1 year before the test or have participated in the&#xD;
             radiopharmaceutical labeling test;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

